To our knowledge, our study is the first to measure the biomarker osteoprotegerin in the urine of DN patients, and the first to show that treatment with minocycline in DN can lower urinary osteoprotegerin excretion. Here, TNFRSF11B is linked to liver dysplastic nodule.